Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TAU-PROTEIN IN CEREBROSPINAL-FLUID - A BIOCHEMICAL MARKER FOR AXONAL DEGENERATION IN ALZHEIMER-DISEASE
Autore:
BLENNOW K; WALLIN A; AGREN H; SPENGER C; SIEGFRIED J; VANMECHELEN E;
Indirizzi:
GOTHENBURG UNIV,MOLNDAL HOSP,DEPT CLIN NEUROSCI,NEUROCHEM UNIT S-43180 MOLNDAL SWEDEN GOTHENBURG UNIV,MOLNDAL HOSP,DEPT CLIN NEUROSCI,PSYCHIAT UNIT S-43180MOLNDAL SWEDEN UNIV BERN,DEPT NEUROSURG BERN SWITZERLAND KLIN PARK ZURICH SWITZERLAND INNOGENET NV GHENT BELGIUM
Titolo Testata:
Molecular and chemical neuropathology
fascicolo: 3, volume: 26, anno: 1995,
pagine: 231 - 245
SICI:
1044-7393(1995)26:3<231:TIC-AB>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
PAIRED HELICAL FILAMENTS; NEUROFIBRILLARY TANGLES; HUMAN BRAIN; VASCULAR DEMENTIA; TEMPORAL CORTEX; PATHOLOGY; HETEROGENEITY; ACCUMULATION; SPECIFICITY; ANTIBODIES;
Keywords:
ALZHEIMER DISEASE (AD); BIOCHEMICAL MARKERS; CEREBROSPINAL FLUID (CSF); TAU PROTEIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
56
Recensione:
Indirizzi per estratti:
Citazione:
K. Blennow et al., "TAU-PROTEIN IN CEREBROSPINAL-FLUID - A BIOCHEMICAL MARKER FOR AXONAL DEGENERATION IN ALZHEIMER-DISEASE", Molecular and chemical neuropathology, 26(3), 1995, pp. 231-245

Abstract

Cerebrospinal fluid (CSF) biochemical markers for Alzheimer disease (AD) would be of great value to improve the clinical diagnostic accuracy of the disorder. As abnormally phosphorylated forms of the microtubule-associated protein tau have been consistently found in the brains of AD patients, and since tau can be detected in CSF, two assays based on several well-defined monoclonal tau antibodies were used to study these proteins in CSF. One assay detects most normal and abnormal formsof tau (CSF-tau), while the other is highly specific for phosphorylated tan (CSF-PHFtau). A marked increase in CSF-PHFtau was found in AD (2230 +/- 930 pg/mL), as compared with controls (640 +/- 230 pg/mL; p <0.0001), vascular dementia, VAD (1610 +/- 840 pg/mL; p < 0.05), frontal Lobe dementia, FLD (1530 +/- 1000 pg/mL; p < 0.05), Parkinson disease, PD (720 +/- 590 pg/mL; p < 0.0001), and patients with major depression (230 +/- 130 pg/mL; p < 0.0001). Parallel results were obtained for CSF-tau. No less than 35/40 (88%) of AD patients had a CSF-PHFtau value higher than the cutoff level of 1140 pg/mL in controls. The present study demonstrates that elevated tau/PHFtau levels are consistentlyfound in CSF of AD patients. However, a considerable overlap is stillpresent with other forms of dementia, both VAD and FLD. CSF-tau and CSF-PHFtau may therefore be useful as a positive biochemical marker, todiscriminate AD from normal aging, PD, and depressive pseudodementia. Further studies are needed to clarify the sensitivity and specificityof these assays, including follow-up studies with neuropathological examinations.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 03:32:40